80322-82-3

Basic information

• Product Name: Triethylene Glycol Dimethanesulfonate
• Synonyms: Triethylene Glycol Dimethanesulfonate;2,2'-[1,2-Ethanediylbis(oxy)]bis-ethanol 1,1'-DiMethanesulfonate;DiMesyl Triethylene Glycol;Triethylene Glycol DiMesylate;MS-PEG2-MS
• CAS NO: 80322-82-3
• Molecular Formula: C₈H₁₈O₈S₂
• Molecular Weight: 306.35372
• Product Categories: Intermediates;Polyethyleneglycol Derivatives
• Mol File: 80322-82-3.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chlroform (Sparingly), Methanol (Slightly)
• CAS DataBase Reference: Triethylene Glycol Dimethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Triethylene Glycol Dimethanesulfonate(80322-82-3)
• EPA Substance Registry System: Triethylene Glycol Dimethanesulfonate(80322-82-3)

Safety Data

• Hazardous Substances Data: 80322-82-3(Hazardous Substances Data)

Usage

Chemical Properties

Orange Oil

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 

Downstream Products

• 98269-24-0 N-(2-methoxybenzyl)monoaza-15-crown-5 
• 235091-02-8 1-benzyloxy-2-(2-{2-[2-(1-benzyloxyethyl-undecyloxy)-ethoxy]-ethoxy}-ethoxy)dodecane 
• 361543-06-8 C₄₀H₆₆O₁₄ 
• 3386-18-3 nonaethylene glycol 
• 17598-96-8 poly(ethylene glycol) 600 
• 361543-07-9 1,2-bis-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethane 
• 361543-12-6 PEODA₁₃ 
• 59559-06-7 1,8-diazido-3,6-dioxaoctane 
• 14098-41-0 dibenzo-21-crown-7 
• 14262-61-4 6,7,9,10,12,13,20,21-octahydrodibenzo[b,h][1,4,7,10,13,16]hexaoxacyclooctadecine 
• 66750-10-5 13-phenyl-1,4,7,10-tetraoxa-13-aza-cyclopentadecane 
• 73171-45-6 C₁₉H₂₅N₅O₆S 
• 524728-92-5 C₆₂H₈₂O₈ 
• 349113-91-3 C₃₆H₅₈O₁₂ 

Relevant articles and documents

Tetrahydroisoquinoline derivative as well as preparation method and medical application thereof

The invention relates to a tetrahydroisoquinoline derivative, a preparation method thereof and medical application of the tetrahydroisoquinoline derivative. Specifically, the invention relates to a tetrahydroisoquinoline derivative as shown in a general formula (I) and a medicinal salt thereof, a preparation method of the tetrahydroisoquinoline derivative and the medicinal salt thereof, and application of the tetrahydroisoquinoline derivative and the medicinal salt thereof as NHE3 inhibitors, particularly as a therapeutic agent for diseases related to body fluid retention or salt overload or gastrointestinal diseases. Wherein the definition of each substituent in the general formula (I) is the same as the definition in the specification.

DIMER COMPOUNDS, AND USE IN BINDING TOXIC REPEATS OF RNA

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are dimeric inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Probing the Existence of a Metastable Binding Site at the β2-Adrenergic Receptor with Homobivalent Bitopic Ligands

Herein, we report the development of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding site (MBS) within the same receptor unit. Previous molecular dynamics studies on ligand binding to the β2-adrenergic receptor (β2AR) suggested that ligands pause at transient, less-conserved MBSs. We envisioned that MBSs can be regarded as allosteric binding sites and targeted by homobivalent bitopic ligands linking two identical pharmacophores. Such ligands were designed based on docking of the antagonist (S)-alprenolol into the OBS and an MBS and synthesized. Pharmacological characterization revealed ligands with similar potency and affinity, slightly increased β2/β1AR-selectivity, and/or substantially slower β2AR off-rates compared to (S)-alprenolol. Truncated bitopic ligands suggested the major contribution of the metastable pharmacophore to be a hydrophobic interaction with the β2AR, while the linkers alone decreased the potency of the orthosteric fragment. Altogether, the study underlines the potential of targeting MBSs for improving the pharmacological profiles of ligands.